{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:43:15Z","timestamp":1770979395498,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4970,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1093\/annonc\/mdj953","type":"journal-article","created":{"date-parts":[[2006,6,28]],"date-time":"2006-06-28T22:52:24Z","timestamp":1151535144000},"page":"v64-v67","source":"Crossref","is-referenced-by-count":37,"special_numbering":"S5","title":["First line chemotherapy in advanced or metastatic NSCLC"],"prefix":"10.1016","volume":"17","author":[{"given":"M.","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gridelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdj953_bb0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials","volume":"311","year":"1995","journal-title":"Br Med J"},{"key":"10.1093\/annonc\/mdj953_bb0015","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.1997.15.8.2996","article-title":"Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology","volume":"15","author":"ASCO Special Article","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0020","first-page":"23","article-title":"Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?","volume":"20","author":"Bunn","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0025","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/annonc\/mdh476","article-title":"Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials","volume":"15","author":"Hotta","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0030","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdj953_bb0040","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparino three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0045","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2004.10.014","article-title":"Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes","volume":"47","author":"Le Chevalier","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdj953_bb0055","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(00)04644-4","article-title":"Platinum-based and non-platinum based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial","volume":"357","author":"Georgoulias","year":"2001","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdj953_bb0060","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.2003.03.195","article-title":"Three-arm randomised study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975","volume":"21","author":"Smit","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0065","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2003.06.099","volume":"21","author":"Gridelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0070","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.2003.12.038","article-title":"Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial","volume":"2","author":"Alberola","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0075","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1200\/JCO.2005.04.016","article-title":"Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial","volume":"23","author":"Georgoulias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0080","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2005.03.045","article-title":"Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature","volume":"23","author":"D\u2019Addario","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0090","doi-asserted-by":"crossref","first-page":"7124a","DOI":"10.1200\/jco.2005.23.16_suppl.7124","volume":"23","author":"Rinaldi","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdj953_bb0095","doi-asserted-by":"crossref","first-page":"7002a","DOI":"10.1200\/jco.2005.23.16_suppl.7002","article-title":"ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p)","volume":"23","author":"Rosell","year":"2005","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/suppl_5\/v64\/476705\/mdj953.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T07:20:34Z","timestamp":1589440834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419381906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":18,"alternative-id":["S0923753419381906"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdj953","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}